title: [Organising the follow-up of biologics].
abstract: Treatment with biologics requires specific evaluation based on assessment of clinical efficacy, of comorbidities and of safety. Although evaluation is mainly clinical, additional laboratory investigations may be needed. The occurrence of events, whether disease-related (infection, dysimmunity, cancer) or not (pregnancy, vaccination), is described in specific guidelines and in notification reports submitted to pharmacovigilance agencies.
authors.affiliation: Service de dermatologie, CHU de Besançon, 2, place Saint-Jacques, 25030 Besançon cedex, France. francois.aubin@univ-fcomte.fr
authors.forename: F
authors.initials: F
authors.lastname: Aubin
mesh_terms: D001688:Biological Products / Q000008:administration & dosage* / Q000009:adverse effects; D000075202:Contraindications; D003729:Dental Care; D003875:Drug Eruptions / Q000209:etiology; D016903:Drug Monitoring; D005334:Fever / Q000150:complications; D006801:Humans; D007239:Infections / Q000150:complications; D009369:Neoplasms / Q000150:complications; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy; D013514:Surgical Procedures, Operative; D014611:Vaccination
chemical_list: D001688:Biological Products